Hypoglycemia

American Journal of Medicine

Volumn 127, Issue 10, 2014, Pages S17-S24

  Morales, Javier ^a   Schneider, Doron ^b  

^a Advanced Internal Medicine Group   (United States)

^b Abington Health   (United States)

Author keywords

Blood glucose management; Diabetes; Hypoglycemia; Insulin treatment; Treatment options

Indexed keywords

GLUCOSE; INSULIN; ANTIDIABETIC AGENT;

ARTICLE; AUTONOMIC DYSFUNCTION; COGNITIVE DEFECT; DISEASE PREDISPOSITION; DISEASE SEVERITY; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEALTH CARE COST; HEALTH CARE POLICY; HUMAN; HYPOGLYCEMIA; INSULIN DEGRADATION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; KIDNEY CLEARANCE; KIDNEY FAILURE; LIFESTYLE MODIFICATION; MEDICAL HISTORY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PRODUCTIVITY; QT PROLONGATION; QUALITY OF LIFE; RISK FACTOR; SELF CARE; SELF MONITORING; TEST STRIP; TREATMENT DURATION; WORKPLACE; AGE; ANAMNESIS; ATTITUDE TO HEALTH; COMPLICATION; COST; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION; ECONOMICS; PREVALENCE; PSYCHOLOGY; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX;

AGE FACTORS; COSTS AND COST ANALYSIS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; MEDICAL HISTORY TAKING; PREVALENCE; QUALITY OF LIFE; RENAL INSUFFICIENCY; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 84921780207     PISSN: 00029343     EISSN: 15557162     Source Type: Journal    
DOI: 10.1016/j.amjmed.2014.07.004     Document Type: Article

References (90)

1. Frier BM. How hypoglycaemia can affect the life of a person with diabetes. Diabetes Metab Res Rev. 2008;24:87-92.
2. Seaquist ER, Anderson J, Childs B, et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care. 2013;36:1384-1395.
3. Frier BM. Defining hypoglycaemia: what level has clinical relevance? Diabetologia. 2009;52:31-34.
4. Graveling AJ, Frier BM. Hypoglycaemia: an overview. Prim Care Diabetes. 2009;3:131-139.
5. Henderson JN, Allen KV, Deary IJ, Frier BM. Hypoglycaemia in insulin-treated Type 2 diabetes: frequency, symptoms and impaired awareness. Diabet Med. 2003;20:1016-1021.
6. Zammitt NN, Streftaris G, Gibson GJ, et al. Modeling the consistency of hypoglycemic symptoms: high variability in diabetes. Diabetes Technol Ther. 2011;13:571-578.
7. El Khoury M, Yousuf F, Martin V, Cohen RM. Pseudohypoglycemia: a cause for unreliable finger-stick glucose measurements. Endocr Pract. 2008;14:337-339.
8. Guillod L, Comte-Perret S, Monbaron D, et al. Nocturnal hypoglycaemias in type 1 diabetic patients: what can we learn with continuous glucose monitoring? Diabetes Metab. 2007;33:360-365.
9. Weber KK, Lohmann T, Busch K, et al. High frequency of unrecognized hypoglycaemias in patients with type 2 diabetes is discovered by continuous glucose monitoring. Exp Clin Endocrinol Diabetes. 2007;115:491-494.
10. Donnelly LA, Morris AD, Frier BM, et al. Frequency and predictors of hypoglycaemia in type 1 and insulin-treated type 2 diabetes: a population-based study. Diabet Med. 2005;22:749-755.
11. Zoungas S, Patel A, Chalmers J, et al. Severe hypoglycemia and risks of vascular events and death. N Engl J Med. 2010;363:1410-1418.
12. Pedersen-Bjergaard U, Pramming S, Heller SR, et al. Severe hypoglycaemia in 1076 adult patients with type 1 diabetes: influence of risk markers and selection. Diabetes Metab Res Rev. 2004;20:479-486.
13. Bonds DE, Miller ME, Dudl J, et al. Severe hypoglycemia symptoms, antecedent behaviors, immediate consequences and association with glycemia medication usage: Secondary analysis of the ACCORD clinical trial data. BMC Endocr Disord. 2012;12:5.
14. Inkster B, Zammitt NN, Frier BM. Drug-induced hypoglycaemia in type 2 diabetes. Expert Opin Drug Saf. 2012;11:597-614.
15. Phung OJ, Scholle JM, Talwar M, Coleman CI. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA. 2010;303: 1410-1418.
16. Tschöpe D, Bramlage P, Binz C, et al. Incidence and predictors of hypoglycaemia in type 2 diabetes - an analysis of the prospective DiaRegis registry. BMC Endocr Disord. 2012;12:23.
17. Watson JM, Jenkins EJ, Hamilton P, et al. Influence of caffeine on the frequency and perception of hypoglycemia in free-living patients with type 1 diabetes. Diabetes Care. 2000;23:455-459.
18. Moen MF, Zhan M, Hsu VD, et al. Frequency of hypoglycemia and its significance in chronic kidney disease. Clin J Am Soc Nephrol. 2009;4: 1121-1127.
19. Ligthelm RJ, Kaiser M, Vora J, Yale JF. Insulin use in elderly adults: risk of hypoglycemia and strategies for care. J Am Geriatr Soc. 2012;60:1564-1570.
20. Bramlage P, Gitt AK, Binz C, et al. Oral antidiabetic treatment in type-2 diabetes in the elderly: balancing the need for glucose control and the risk of hypoglycemia. Cardiovasc Diabetol. 2012;11:122.
21. Zammitt NN, Frier BM. Hypoglycemia in type 2 diabetes: pathophysiology, frequency, and effects of different treatment modalities. Diabetes Care. 2005;28:2948-2961.
22. Lin CH, Sheu WH. Hypoglycaemic episodes and risk of dementia in diabetes mellitus: 7-year follow-up study. J Intern Med. 2013;273: 102-110.
23. Strachan MW, Reynolds RM, Marioni RE, Price JF. Cognitive function, dementia and type 2 diabetes mellitus in the elderly. Nat Rev Endocrinol. 2011;7:108-114.
24. Bremer JP, Jauch-Chara K, Hallschmid M, et al. Hypoglycemia unawareness in older compared with middle-aged patients with type 2 diabetes. Diabetes Care. 2009;32:1513-1517.
25. Munshi MN, Segal AR, Suhl E, et al. Frequent hypoglycemia among elderly patients with poor glycemic control. Arch Intern Med. 2011;171:362-364.
26. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: postion statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35:1364-1379, Erratum in Diabetes Care. 2013; 36:490.
27. Bakatselos SO. Hypoglycemia unawareness. Diabetes Res Clin Pract. 2011;93:S92-S96.
28. Unger J, Parkin C. Recognition, prevention, and proactive management of hypoglycemia in patients with type 1 diabetes mellitus. Postgrad Med. 2011;123:71-80.
29. Schopman JE, Geddes J, Frier BM. Frequency of symptomatic and asymptomatic hypoglycaemia in type 1 diabetes: effect of impaired awareness of hypoglycaemia. Diabet Med. 2011;28:352-355.
30. Banarer S, Cryer PE. Sleep-related hypoglycemia-associated autonomic failure in type 1 diabetes: reduced awakening from sleep during hypoglycemia. Diabetes. 2003;52:1195-1203.
31. Jones TW, Porter P, Sherwin RS, et al. Decreased epinephrine responses to hypoglycemia during sleep. N Engl J Med. 1998;338: 1657-1662.
32. Cryer PE. Severe hypoglycemia predicts mortality in diabetes. Diabetes Care. 2012;35:1814-1816.
33. McCoy RG, Van Houten HK, Ziegenfuss JY, et al. Increased mortality of patients with diabetes reporting severe hypoglycemia. Diabetes Care. 2012;35:1897-1901.
34. Johnston SS, Conner C, Aagren M, et al. Evidence linking hypoglycemic events to an increased risk of acute cardiovascular events in patients with type 2 diabetes. Diabetes Care . 2011;34: 1164-1170.
35. Gimenéz M, Gilabert R, Monteagudo J, et al. Repeated episodes of hypoglycemia as a potential aggravating factor for preclinical atherosclerosis in subjects with type 1 diabetes. Diabetes Care. 2011;34: 198-203.
36. Gogitidze Joy N, Hedrington MS, Briscoe VJ, et al. Effects of acute hypoglycemia on inflammatory and pro-atherothrombotic biomarkers in individuals with type 1 diabetes and healthy individuals. Diabetes Care. 2010;33:1529-1535.
37. Wright RJ, Newby DE, Stirling D, et al. Effects of acute insulininduced hypoglycemia on indices of inflammation: putative mechanism for aggravating vascular disease in diabetes. Diabetes Care. 2010;33:1591-1597.
38. Snell-Bergeon JK, Wadwa RP. Hypoglycemia, diabetes, and cardiovascular disease. Diabetes Technol Ther. 2012;14(Suppl 1):S51-S58.
39. Laitinen T, Lyyra-Laitinen T, Huopio H, et al. Electrocardiographic alterations during hyperinsulinemic hypoglycemia in healthy subjects. Ann Noninvasive Electrocardiol. 2008;13:97-105.
40. Christensen TF, Lewinski I, Kristensen LE, et al. QT interval prolongation during rapid fall in blood glucose in type 1 diabetes. Comput Cardiol. 2007;34:345-348.
41. Asvold BO, Sand T, Hestad K, Bjorgaas MR. Cognitive function in type 1 diabetic adults with early exposure to severe hypoglycemia: a 16-year follow-up study. Diabetes Care. 2010;33:1945-1947.
42. Whitmer RA, Karter AJ, Yaffe K, et al. Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA. 2009;301:1565-1572.
43. Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med. 2011;365:2002-2012.
44. Parsaik AK, Carter RE, Myers LA, et al. Population-based study of hypoglycemia in patients with type 1 diabetes mellitus requiring emergency medical services. Endocr Pract. 2012;18:834-841.
45. Parsaik AK, Carter RE, Myers LA, et al. Hypoglycemia requiring ambulance services in patients with type 2 diabetes is associated with increased long-term mortality. Endocr Pract. 2013;19:29-35.
46. Davis RE, Morrissey M, Peters JR, et al. Impact of hypoglycaemia on quality of life and productivity in type 1 and type 2 diabetes. Curr Med Res Opin. 2005;21:1477-1483.
47. Bullano MF, Al-Zakwani IS, Fisher MD, et al. Differences in hypoglycemia event rates and associated cost-consequence in patients initiated on long-acting and intermediate-acting insulin products. Curr Med Res Opin. 2005;21:291-298.
48. Bron M, Marynchenko M, Yang H, et al. Hypoglycemia, treatment discontinuation, and costs in patients with type 2 diabetes mellitus on oral antidiabetic drugs. Postgrad Med. 2012;124:124-132.
49. Williams SA, Pollack MF, Dibonaventura M. Effects of hypoglycemia on health-related quality of life, treatment satisfaction and healthcare resource utilization in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2011;91:363-370.
50. Williams SA, Shi L, Brenneman SK, et al. The burden of hypoglycemia on healthcare utilization, costs, and quality of life among type 2 diabetes mellitus patients. J Diabetes Complications . 2012;26: 399-406.
51. Harris SB, Leiter LA, Yale JF, et al. Out-of-pocket costs of managing hyperglycemia and hypoglycemia in patients with type 1 diabetes and insulin-treated type 2 diabetes. Can J Diabetes. 2007; 31:25-33.
52. Allen KV, Frier BM. Nocturnal hypoglycemia: clinical manifestations and therapeutic strategies toward prevention. Endocr Pract. 2003;9: 530-543.
53. Brod M, Christensen T, Bushnell DM. Impact of nocturnal hypoglycemic events on diabetes management, sleep quality, and next-day function: results from a four-country survey. J Med Econ. 2012;15: 77-86.
54. Brod M, Pohlman B, Wolden M, Christensen T. Non-severe nocturnal hypoglycemic events: experience and impacts on patient functioning and well-being. Qual Life Res. 2013;22:997-1004.
55. Brod M, Christensen T, Bushnell DM. The impact of non-severe hypoglycemic events on daytime function and diabetes management among adults with type 1 and type 2 diabetes. J Med Econ. 2012;15: 869-877.
56. Brod M, Christensen T, Thomsen TL, Bushnell DM. The impact of non-severe hypoglycemic events on work productivity and diabetes management. Value Health. 2011;14:665-671.
57. Alvarez-Guisasola F, Tofe PS, Krishnarajah G, et al. Hypoglycaemic symptoms, treatment satisfaction, adherence and their associations with glycaemic goal in patients with type 2 diabetes mellitus: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) Study. Diabetes Obes Metab. 2008; 10(Suppl 1):25-32.
58. Alvarez-Guisasola F, Yin DD, Nocea G, et al. Association of hypoglycemic symptoms with patients' rating of their health-related quality of life state: a cross sectional study. Health Qual Life Outcomes. 2010;8:86.
59. Green AJ, Fox KM, Grandy S. Self-reported hypoglycemia and impact on quality of life and depression among adults with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2012;96:313-318.
60. Lundkvist J, Berne C, Bolinder B, Jonsson L. The economic and quality of life impact of hypoglycemia. Eur J Health Econ. 2005;6: 197-202.
61. Marrett E, Stargardt T, Mavros P, Alexander CM. Patient-reported outcomes in a survey of patients treated with oral antihyperglycaemic medications: associations with hypoglycaemia and weight gain. Diabetes Obes Metab. 2009;11:1138-1144.
62. Sheu WH, Ji LN, Nitiyanant W, et al. Hypoglycemia is associated with increased worry and lower quality of life among patients with type 2 diabetes treated with oral antihyperglycemic agents in the Asia-Pacific region. Diabetes Res Clin Pract. 2012;96:141-148.
63. Vexiau P, Mavros P, Krishnarajah G, et al. Hypoglycaemia in patients with type 2 diabetes treated with a combination of metformin and sulphonylurea therapy in France. Diabetes Obes Metab. 2008; 10(Suppl 1):16-24.
64. Edelman S, Pettus J. Challenges associated with insulin therapy in type 2 diabetes mellitus. Am J Med. 2013;127(Suppl 1):S11-S16.
65. Centers for Medicare and Medicaid Services. Last updated 2013. Physician Quality Reporting System. Available at: http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/PQRS/index.html?redirect=/pqrs. Accessed December 2013.
66. National Committee for Quality Assurance. Last updated 2013. HEDIS & Performance Measurement. Available at: http://www.ncqa.org/HEDISQualityMeasurement.aspx. Accessed December 2013.
67. Centers for Medicare and Medicaid Services. Last updated 2012. CMS Proposals for the Physician Value-Based Payment Modifier under the Medicare Physician Fee Schedule. Available at: http://www.cms.gov/Outreach-and-Education/Outreach/NPC/Downloads/8-1-12-VBPM-NPC-Presentation.pdf. Accessed December 2013.
68. Lawton J, Rankin D, Cooke DD, et al. Self-treating hypoglycaemia: a longitudinal qualitative investigation of the experiences and views of people with Type 1 diabetes. Diabet Med. 2013;30:209-215.
69. Tan P, Chen HC, Taylor B, Hegney D. Experience of hypoglycaemia and strategies used for its management by community-dwelling adults with diabetes mellitus: a systematic review. Int J Evid Based Healthc. 2012;10:169-180.
70. Hermanns N, Caputo S, Dzida G, et al. Screening, evaluation and management of depression in people with diabetes in primary care. Prim Care Diabetes. 2013;7:1-10.
71. Vindedzis S, Marsh B, Sherriff J, et al. Dietary treatment of hypoglycaemia: should the Australian recommendation be increased? Intern Med J. 2012;42:830-833.
72. Husband AC, Crawford S, McCoy LA, Pacaud D. The effectiveness of glucose, sucrose, and fructose in treating hypoglycemia in children with type 1 diabetes. Pediatr Diabetes. 2010;11:154-158.
73. Cryer PE. Hypoglycemia in type 1 diabetes mellitus. Endocrinol Metab Clin North Am. 2010;39:641-654.
74. Cox DJ, Gonder-Frederick L, Polonsky W, et al. Blood glucose awareness training (BGAT-2): long-term benefits. Diabetes Care. 2001;24:637-642.
75. Hermanns N, Kulzer B, Kubiak T, et al. The effect of an education programme (HyPOS) to treat hypoglycaemia problems in patients with type 1 diabetes. Diabetes Metab Res Rev. 2007;23:528-538.
76. Hermanns N, Kulzer B, Krichbaum M, et al. Long-term effect of an education program (HyPOS) on the incidence of severe hypoglycemia in patients with type 1 diabetes. Diabetes Care. 2010; 33:e36.
77. Deacon CF, Mannucci E, Ahren B. Glycaemic ef ficacy of glucagonlike peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis. Diabetes Obes Metab. 2012;14: 762-767.
78. Heise T, Hermanski L, Nosek L, et al. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steadystate conditions in type 1 diabetes. Diabetes Obes Metab. 2012;14: 859-864.
79. Little S, Shaw J, Home P. Hypoglycemia rates with basal insulin analogs. Diabetes Technol Ther. 2011;13(Suppl 1):S53-S64.
80. Tibaldi JM. Evolution of insulin development: focus on key parameters. Adv Ther. 2012;29:590-619.
81. Heise T, Pieber TR. Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies. Diabetes Obes Metab. 2007;9:648-659.
82. Heise T, Nosek L, Bottcher SG, et al. Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes. Diabetes Obes Metab. 2012;14:944-950.
83. Monami M, Marchionni N, Mannucci E. Long-acting insulin analogues vs. NPH human insulin in type 1 diabetes. A meta-analysis. Diabetes Obes Metab. 2009;11:372-378.
84. Monami M, Marchionni N, Mannucci E. Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis. Diabetes Res Clin Pract. 2008;81:184-189.
85. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009;15:540-559.
86. Ratner R, Gough SC, Mathieu C, et al. Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials. Diabetes Obes Metab. 2013;15:175-184.
87. Qu Y, Jacober SJ, Zhang Q, et al. Rate of hypoglycemia in insulintreated patients with type 2 diabetes can be predicted from glycemic variability data. Diabetes Technol Ther. 2012;14:1008-1012.
88. Monnier L, Wojtusciszyn A, Colette C, Owens D. The contribution of glucose variability to asymptomatic hypoglycemia in persons with type 2 diabetes. Diabetes Technol Ther. 2011;13:813-818.
89. Cox DJ, Gonder-Frederick L, Ritterband L, et al. Prediction of severe hypoglycemia. Diabetes Care. 2007;30:1370-1373.
90. Vora J, Bain SC, Damci T, et al. Incretin-based therapy in combination with basal insulin: a promising tactic for the treatment of type 2 diabetes. Diabetes Metab. 2013;39:6-15.